Oral semaglutide demonstrated significant reduction in blood sugar in PIONEER trial
Oral semaglutide, an investigational GLP-1 receptor agonist taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. June 23, 2018